Audited Financial Results for the year ended 31 March, 2026
SAILIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts less than Nifty Smallcap 250 and 3.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sai Life Sciences reported strong full-year results with standalone revenue growing 31% to Rs 21,532 million from Rs 16,420 million. Profit after tax nearly doubled to Rs 3,415 million from Rs 1,735 million, representing 97% PAT growth. Basic EPS improved to Rs 16.27 from Rs 9.00. Consolidated revenue stood at Rs 21,925 million with PAT of Rs 3,489 million. The company had exceptional items of Rs 80.01 million related to Labour Code implementation. Operating cash flow remained strong at Rs 4,953 million. Auditors Deloitte Haskins & Sells LLP issued an unmodified opinion on the annual results. The company completed its IPO in December 2024 and deployed Rs 9,099 million of proceeds primarily for debt repayment.
The results show robust growth with PAT nearly doubling year-on-year, indicating strong operational performance and margin expansion. The clean audit opinion without any qualifications supports financial reliability. Shareholders can expect positive sentiment given the exceptional revenue and profit growth.